TrialCardiovascular drugs and therapy2014

Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.

John J P Kastelein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.